ExpreS2ion Biotech Holding
5.09 SEK
+0.79 %
Less than 1K followers
EXPRS2
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for ExpreS2ion Biotech Holding
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 13.8 | 15.3 | 12.2 | 5.1 | 7.1 | 3.0 | 3.7 |
| growth-% | 10.4 % | -19.8 % | -58.4 % | 38.5 % | -57.3 % | 21.5 % | |
| EBITDA | -15.2 | -28.8 | -46.6 | -126.4 | -104.4 | -104.2 | -42.8 |
| EBIT | -18.1 | -31.7 | -48.4 | -127.6 | -106.0 | -67.7 | -44.3 |
| Profit before taxes | -19.1 | -35.2 | -47.5 | -126.6 | -104.6 | -44.6 | -44.2 |
| Net income | -16.7 | -32.0 | -43.9 | -118.6 | -96.0 | -36.4 | -38.1 |
| EPS | -35.22 | -62.25 | -46.56 | -107.45 | -71.10 | -13.70 | -13.39 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -110.2 % | -188.4 % | -380.8 % | -2,483.1 % | -1,480.3 % | -3,460.5 % | -1,170.4 % |
| EBIT-% | -131.0 % | -207.5 % | -395.6 % | -2,507.1 % | -1,503.1 % | -2,249.2 % | -1,210.6 % |
| ROE | 1,548.0 % | -33.8 % | -31.3 % | -114.8 % | -157.5 % | -56.5 % | -106.7 % |
| ROI | -89.3 % | -26.9 % | -28.9 % | -86.3 % | -129.3 % | -34.8 % | -58.5 % |